CN111000973A - Composition with gout improving effect and application thereof - Google Patents
Composition with gout improving effect and application thereof Download PDFInfo
- Publication number
- CN111000973A CN111000973A CN201911332413.9A CN201911332413A CN111000973A CN 111000973 A CN111000973 A CN 111000973A CN 201911332413 A CN201911332413 A CN 201911332413A CN 111000973 A CN111000973 A CN 111000973A
- Authority
- CN
- China
- Prior art keywords
- parts
- gout
- extract
- composition
- effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8967—Lilium, e.g. tiger lily or Easter lily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
Abstract
The invention discloses a composition with a gout improving effect, which comprises the following raw material components in parts by weight: 1-10 parts of soybean peptide, 0.1-2 parts of artichoke leaf extract, 0.1-2 parts of curcumin, 0.1-2 parts of sour cherry powder, 0.1-2 parts of bonito peptide, 0.1-2 parts of aronia melanocarpa fruit, 0.1-2 parts of celery seed extract, 0.1-2 parts of grape seed extract and 0.1-2 parts of silybum marianum extract; after the active ingredients are compounded according to a specific proportion, the synergistic effect can be achieved on the effects of reducing the uric acid level, resisting inflammation and the like, the effect of treating gout is greatly improved, the antioxidant effect can be further improved, the organism is helped to clear away redundant free radicals, the functions of damaged cells and organs are improved, the metabolism of the organism is promoted, and the risk of gout recurrence is reduced.
Description
Technical Field
The invention relates to the field of medicines, health-care products or foods, in particular to a composition with a gout improving effect and application thereof.
Background
Gout is also called hyperuricemia and purine metabolic disorder, and belongs to arthritis. Gout is the disorder of metabolism of purine substances in human bodies, the increase or reduction of synthesis or excretion of uric acid causes hyperuricemia, and when the concentration of blood uric acid is too high, uric acid is deposited in joints, cartilages and kidneys in the form of sodium salt to cause inflammatory reaction of tissue foreign bodies. Various parts of the human body are frequently suffered from severe pain of joints.
At present, most of the existing medicines for clinically treating gout cause physical damage, take effect slowly, have long treatment course, finally can not eradicate the gout, and need to take the medicines for a long time to relieve symptoms, so that the medicines are dependent on each other in the long term, and great harm is caused to the mind and body of a patient.
Therefore, the composition with the gout improving effect and no side effect is developed, and has important significance for gout patients.
Disclosure of Invention
In view of this, the invention provides a composition with gout improving effect, which has good gout improving effect and no side effect, and also provides a preparation method and application of the composition.
The composition with the effect of improving gout comprises the following raw material components in parts by weight: 1-10 parts of soybean peptide, 0.1-2 parts of artichoke leaf extract, 0.1-2 parts of curcumin, 0.1-2 parts of sour cherry powder, 0.1-2 parts of bonito peptide, 0.1-2 parts of aronia melanocarpa, 0.1-2 parts of celery seed extract, 0.1-2 parts of grape seed extract and 0.1-2 parts of silybum marianum extract;
further, the paint comprises the following raw material components in parts by weight: 3-8 parts of soybean peptide, 0.5-1.5 parts of artichoke leaf extract, 0.5-1.5 parts of curcumin, 0.5-1.5 parts of sour cherry powder, 0.5-1.5 parts of bonito peptide, 0.5-1.5 parts of aronia melanocarpa, 0.5-1.5 parts of celery seed extract, 0.5-1.5 parts of grape seed extract and 0.5-1.5 parts of silybum marianum extract;
further, the paint comprises the following raw material components in parts by weight: 5 parts of peptide, 1 part of artichoke leaf extract, 1 part of curcumin, 1 part of sour cherry powder, 1 part of bonito peptide, 1 part of aronia melanocarpa, 1 part of celery seed extract, 1 part of grape seed extract and 1 part of silybum marianum extract;
furthermore, one or more traditional Chinese medicines for improving or treating concurrent symptoms can be added into the composition;
further, the application in preparing foods, medicines or health products for improving gout.
One or more traditional Chinese medicines for improving or treating concurrent symptoms can be added into the composition with the effect of improving gout, such as 0.1-0.5 part of Chinese alpine rush: the medicine is used for eliminating inflammation caused by gout, can help to relieve distending pain and discomfort and further relieve sore pain of joints and muscles, and also helps to discharge uric acid and toxin which are gathered in the joints and muscles out of the body, so that uric acid and toxin which are accumulated for many years are prevented from affecting an affected part and causing the sore pain and the inflammation; adding 0.1-0.5 part of dandelion: has certain effects of reducing swelling and resolving masses, and can also play a certain auxiliary effect on treating gout; 0.1-0.5 parts of gardenia, 0.1-0.5 parts of chicory, 0.1-0.5 parts of lily: the combination of chicory and lily promotes the reduction of uric acid, and gardenia promotes the excretion of uric acid; 0.1-0.5 parts of kudzu root: reduce purine synthesis, reduce uric acid production, accelerate purine decomposition, and promote purine excretion.
The composition can be added with conventional auxiliary materials and prepared into food, medicine or health care products acceptable in medicine, dietetics or health care science according to the conventional process; the health product or medicine can be made into liquid granule, powder, tablet, capsule or other conventional dosage forms.
The conventional auxiliary materials comprise: bulking agent, disintegrating agent, lubricant, suspending agent, binder, sweetener, correctant, antiseptic, etc.
Wherein:
the filler comprises: starch, pregelatinized starch, lactose, mannitol, chitin, microcrystalline cellulose, sucrose, etc.;
the disintegrating agent comprises: starch, pregelatinized starch, microcrystalline cellulose, sodium carboxymethyl starch, cross-linked polyvinylpyrrolidone, low-substituted hydroxypropylcellulose, cross-linked sodium carboxymethyl cellulose, etc.;
the lubricant comprises: magnesium stearate, sodium lauryl sulfate, talc, silica, and the like;
the suspending agent comprises: polyvinylpyrrolidone, microcrystalline cellulose, sucrose, agar, hydroxypropyl methylcellulose, and the like;
the adhesive comprises starch slurry, polyvinylpyrrolidone, hydroxypropyl methylcellulose, etc.;
the sweetener comprises: saccharin sodium, aspartame, sucrose, sodium cyclamate, glycyrrhetinic acid, and the like;
the flavoring agent comprises: sweeteners and various essences;
the preservative comprises: parabens, benzoic acid, sodium benzoate, sorbic acid and its salts, benzalkonium bromide, chloroacetidine acetate, eucalyptus oil, etc.
The invention has the beneficial effects that:
when the composition is used for screening the components, the functional complementation is fully considered, the synergy among the components is realized, the side effect is low when the composition is eaten, and the gout symptom can be effectively relieved.
The small molecular peptide is the key for quickly reducing uric acid and dissolving tophus, can inhibit purine synthesis, reduce uric acid, dissolve tophus, repair damaged liver and kidney cells, has no toxic or side effect, and can be eaten for a long time; not all peptides are small-molecule peptides, and the peptides with the molecular weight of 1000-5000 daltons are called large peptides; the peptide can be named as small molecular peptide only when the molecular peptide is between 180 and 1000 daltons. The artichoke leaf extract not only can inhibit the activity of xanthine oxidase to reduce the uric acid level, but also has antioxidant activity, can clear redundant free radicals in a body, has a protective effect on the liver, and can enhance the detoxification function of the liver; curcumin can reduce production of uric acid, reduce serum uric acid content, promote urine discharge, has excellent antioxidant and anti-inflammatory effects, and can help organism resist inflammation, improve gout, and repair injury; the sour cherry contains a large amount of higher anthocyanidin which is not contained in fruits such as blueberries, raspberries and the like, contains more total phenols and a plurality of auxiliary compounds such as compounds for regulating inflammation and the like, does not contain sugar and heat, has very excellent antioxidant and anti-inflammatory effects, can help an organism to resist inflammation, remove redundant free radicals in the organism and repair the damage caused by the redundant free radicals, not only can improve gout, but also can reduce the recurrence risk of gout; the bonito peptide has remarkable effects of resisting oxidation, reducing uric acid and the like, and can quickly reduce the content of acidic substances in a body; the aronia melanocarpa fruit contains abundant substances such as anthocyanin, flavone and polyphenol, has strong effects of resisting oxidation and inflammation, and the like, and can help the organism to resist inflammation, improve gout, remove redundant free radicals in the organism and repair the injury caused by the free radicals; the celery seed extract has remarkable diuretic, anti-inflammatory and analgesic effects, can remarkably reduce serum uric acid level, and has excellent effect of treating gout; the grape seed extract has excellent oxidation resistance, can remove redundant free radicals in a body, repair damaged cells, reduce purine content, reduce deposition of uric acid in blood, joints and the like, further relieve gout symptoms, promote metabolism and discharge toxins and wastes accumulated in the body of a gout patient; the silybum marianum extract can improve the liver function, enhance the toxin expelling function of the liver, discharge toxin and waste accumulated in the body of a gout patient, has excellent oxidation resistance, can remove redundant free radicals in the body and repair damaged cells.
After the active ingredients are compounded according to a specific proportion, the synergistic effect can be achieved on the effects of reducing the uric acid level, resisting inflammation and the like, the effect of treating gout is greatly improved, the antioxidant effect can be further improved, the organism is helped to clear away redundant free radicals, the functions of damaged cells and organs are improved, the metabolism of the organism is promoted, and the risk of gout recurrence is reduced.
In addition, the components adopted in the composition have no side effect, the cost is low, the components are easy to obtain, the proper proportion is provided after the mutual synergistic action among the components is fully considered, the components can be well absorbed by a human body after being compounded according to the proportion, the mutual coordination and the synergistic action among the components can be fully exerted after being absorbed, and the composition with good treatment effect and no side effect and capable of improving the gout is prepared.
Detailed Description
Example one
The embodiment provides a composition with an effect of improving gout, which comprises the following raw material components in parts by weight: 1 part of soybean peptide, 0.1 part of artichoke leaf extract, 0.1 part of curcumin, 0.1 part of sour cherry powder, 0.1 part of bonito peptide, 0.1 part of aronia melanocarpa fruit, 0.1 part of celery seed extract, 0.1 part of grape seed extract and 0.1 part of silybum marianum extract, and the raw materials are mixed in a multidimensional mixer to prepare the product with the effect of improving gout.
Example two
The embodiment provides a composition with an effect of improving gout, which comprises the following raw material components in parts by weight: 10 parts of peptide, 2 parts of artichoke leaf extract, 2 parts of curcumin, 2 parts of sour cherry powder, 2 parts of bonito peptide, 2 parts of aronia melanocarpa fruit, 2 parts of celery seed extract, 2 parts of grape seed extract and 2 parts of silybum marianum extract.
EXAMPLE III
The embodiment provides a composition with an effect of improving gout, which comprises the following raw material components in parts by weight: 3 parts of peptide, 0.5 part of artichoke leaf extract, 0.5 part of curcumin, 0.5 part of sour cherry powder, 0.5 part of bonito peptide, 0.5 part of aronia melanocarpa fruit, 0.5 part of celery seed extract, 0.5 part of grape seed extract and 0.5 part of silybum marianum extract.
Example four
The embodiment provides a composition with an effect of improving gout, which comprises the following raw material components in parts by weight: 8 parts of peptide, 1.5 parts of artichoke leaf extract, 1.5 parts of curcumin, 1.5 parts of sour cherry powder, 1.5 parts of bonito peptide, 1.5 parts of aronia melanocarpa fruit, 1.5 parts of celery seed extract, 1.5 parts of grape seed extract and 1.5 parts of silybum marianum extract.
EXAMPLE five
The embodiment provides a composition with an effect of improving gout, which comprises the following raw material components in parts by weight: 8 parts of peptide, 1 part of artichoke leaf extract, 0.5 part of curcumin, 1.5 parts of sour cherry powder, 0.5 part of bonito peptide, 1.5 parts of aronia melanocarpa fruit, 0.5 part of celery seed extract, 0.1 part of grape seed extract and 1.5 parts of silybum marianum extract.
EXAMPLE six
The embodiment provides a composition with an effect of improving gout, which comprises the following raw material components in parts by weight: 10 parts of peptide, 0.1 part of artichoke leaf extract, 2 parts of curcumin, 0.1 part of sour cherry powder, 2 parts of bonito peptide, 0.1 part of aronia melanocarpa fruit, 2 parts of celery seed extract, 0.1 part of grape seed extract and 0.1 part of silybum marianum extract.
EXAMPLE seven
The embodiment provides a composition with an effect of improving gout, which comprises the following raw material components in parts by weight: 1 part of soybean peptide, 0.1 part of artichoke leaf extract, 0.1 part of curcumin, 0.1 part of sour cherry powder, 0.1 part of bonito peptide, 0.1 part of aronia melanocarpa fruit, 0.1 part of celery seed extract, 0.1 part of grape seed extract, 0.1 part of silybum marianum extract and 0.1 part of cat grass. The product obtained by the embodiment has better effect than the embodiment.
Example eight
The embodiment provides a composition with an effect of improving gout, which comprises the following raw material components in parts by weight: 1 part of soybean peptide, 0.1 part of artichoke leaf extract, 0.1 part of curcumin, 0.1 part of sour cherry powder, 0.1 part of bonito peptide, 0.1 part of aronia melanocarpa fruit, 0.1 part of celery seed extract, 0.1 part of grape seed extract, 0.1 part of silybum marianum extract and 0.1 part of dandelion. The product obtained by the embodiment has better effect than the embodiment.
Example nine
The embodiment provides a composition with an effect of improving gout, which comprises the following raw material components in parts by weight: 1 part of soybean peptide, 0.1 part of artichoke leaf extract, 0.1 part of curcumin, 0.1 part of sour cherry powder, 0.1 part of bonito peptide, 0.1 part of aronia melanocarpa fruit, 0.1 part of celery seed extract, 0.1 part of grape seed extract, 0.1 part of silybum marianum extract and 0.1 part of kudzu root.
Example ten
The embodiment provides a composition with an effect of improving gout, which comprises the following raw material components in parts by weight: 1 part of soybean peptide, 0.1 part of artichoke leaf extract, 0.1 part of curcumin, 0.1 part of sour cherry powder, 0.1 part of bonito peptide, 0.1 part of aronia melanocarpa fruit, 0.1 part of celery seed extract, 0.1 part of grape seed extract, 0.1 part of silybum marianum extract, 0.1 part of gardenia, 0.1 part of chicory and 0.1 part of lily. The product effect obtained by the embodiment is better than that of the embodiment seven, eight and nine.
The raw materials of the embodiment are mixed in a multidimensional mixer to prepare the product with the effect of improving gout.
The raw materials adopted in the above embodiments can be purchased, and conventional auxiliary materials can be added into the composition provided in the above embodiments to prepare food, medicine or health care product acceptable in medicine, dietetics or health care science according to a conventional process, wherein the conventional auxiliary materials comprise: bulking agent, disintegrating agent, lubricant, suspending agent, binder, sweetener, correctant, antiseptic, etc.
The raw materials used in this example were all available commercially.
In the above examples, examples 2 to 10 are superior to example 1.
Comparative example 1
The embodiment provides a composition with an effect of improving gout, which comprises the following raw material components in parts by weight: 1 part of soybean peptide, 0.1 part of glabrous greenbrier rhizome, 0.1 part of curcumin, 0.1 part of sour cherry powder, 0.1 part of bonito peptide, 0.1 part of aronia melanocarpa fruit, 0.1 part of celery seed extract, 0.1 part of grape seed extract and 0.1 part of silybum marianum extract, and the raw materials are mixed in a multi-dimensional mixer to prepare the product with the effect of improving gout.
In the embodiment, the artichoke leaf extract is replaced by the rhizoma smilacis glabrae, and the rhizoma smilacis glabrae can be used for detoxifying and dehumidifying patients with gout when being used for treatment, so that the effect of reducing the concentration of uric acid is achieved. However, the effect on the product is obviously reduced compared with the first example after the artichoke leaf extract is replaced by the rhizoma smilacis glabrae, and the test example is shown.
Comparative example 2
The embodiment provides a composition with an effect of improving gout, which comprises the following raw material components in parts by weight: 1 part of soybean peptide, 0.1 part of artichoke leaf extract, 0.1 part of curcumin, 0.1 part of sour cherry powder, 0.1 part of bonito peptide, 0.1 part of plantain seed, 0.1 part of celery seed extract, 0.1 part of grape seed extract and 0.1 part of silybum marianum extract, and the raw materials are mixed in a multidimensional mixer to prepare the product with the effect of improving gout.
Semen plantaginis contains adenine succinic acid, and can inhibit adenylic enzyme, so that hypoxanthine and xanthine cannot be converted into uric acid, and can rapidly reduce blood uric acid concentration and reduce excretion of uric acid, thereby inhibiting renal calculus and tophus. However, in this example, the effect was significantly reduced compared to the first example when the Aronia melanocarpa fruit was replaced with psyllium, as shown in the test examples.
Comparative example 3
The embodiment provides a composition with an effect of improving gout, which comprises the following raw material components in parts by weight: 1 part of soybean peptide, 0.1 part of artichoke leaf extract, 0.1 part of curcumin, 0.1 part of sour cherry powder, 0.1 part of bonito peptide, 0.1 part of aronia melanocarpa fruit, 0.1 part of grape seed extract and 0.1 part of silybum marianum extract, and the raw materials are mixed in a multidimensional mixer to prepare the product with the effect of improving gout.
In this example, the effect of the product was significantly reduced after removing the celery seed extract, as compared to the first example, see the experimental examples.
Comparative example 4
The embodiment provides a composition with an effect of improving gout, which comprises the following raw material components in parts by weight: 1 part of soybean peptide, 0.1 part of artichoke leaf extract, 0.1 part of curcumin, 0.1 part of sour cherry powder, 0.1 part of bonito peptide, 0.1 part of aronia melanocarpa fruit, 0.1 part of celery seed extract and 0.1 part of grape seed extract, and the raw materials are mixed in a multidimensional mixer to prepare the product with the effect of improving gout.
After the silybum marianum extract is removed, the product effect is lower than that of the comparative example 3.
Test example: the effect on blood uric acid in a mouse hyperuricemia model was tested using example 1:
1) male ICR rats were randomly divided into 4 groups of 20 each (including normal control group, model group, test group (example 1, comparative example 2, comparative example 3) and positive drug group (allopurinol));
2) potassium oxonate: preparing 1.6g/100ml of suspension, and performing intraperitoneal injection once according to the dose of 300mg/kg of body mass;
3) allopurinol: prepared into 110mg/100ml, and is intragastrically administered 1 time per day according to the dose of 16mg/kg body mass.
4) Normal control group and model group are perfused with normal saline, test group is perfused with 0.6g/kg for feeding, positive drug group is perfused with 25mg/kg for feeding, 1 time a day, after 7 days, except for the control group, the rest groups are perfused with potassium oxonate for 300mg/kg in abdominal cavity of mice 1h before the last feeding, after 1h, the groups are perfused with stomach for feeding, after 1h, the groups are used for removing eyeballs and taking blood, after standing in water bath (37 ℃) until layering, 1800r/min is centrifuged for 10min, serum is taken for measuring blood uric acid value, and differences among groups are compared, and the results are as follows:
| group of | Blood uric acid level (U/L) |
| Control group | 120.77±17.15 |
| Model set | 210.78±26.11 |
| Test set (example 1) | 180.08±13.31 |
| Positive drug group | 140.79±22.54 |
| Test set (comparative example 1) | 205.89±24.32 |
| Test set (comparative example 2) | 206.45±23.45 |
| Test set (comparative example 3) | 203.37±26.78 |
Finally, the above embodiments are only for illustrating the technical solutions of the present invention and not for limiting, although the present invention has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions may be made to the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention, and all of them should be covered in the claims of the present invention.
Claims (5)
1. A composition with gout improving effect is characterized in that: the material comprises the following raw materials in parts by weight: 1-10 parts of soybean peptide, 0.1-2 parts of artichoke leaf extract, 0.1-2 parts of curcumin, 0.1-2 parts of sour cherry powder, 0.1-2 parts of bonito peptide, 0.1-2 parts of aronia melanocarpa fruit, 0.1-2 parts of celery seed extract, 0.1-2 parts of grape seed extract and 0.1-2 parts of silybum marianum extract.
2. The composition for improving gout efficacy of claim 1, wherein: the material comprises the following raw materials in parts by weight: 3-8 parts of soybean peptide, 0.5-1.5 parts of artichoke leaf extract, 0.5-1.5 parts of curcumin, 0.5-1.5 parts of sour cherry powder, 0.5-1.5 parts of bonito peptide, 0.5-1.5 parts of aronia melanocarpa, 0.5-1.5 parts of celery seed extract, 0.5-1.5 parts of grape seed extract and 0.5-1.5 parts of silybum marianum extract.
3. The composition with efficacy in improving gout according to claim 2, wherein: the material comprises the following raw materials in parts by weight: 5 parts of peptide, 1 part of artichoke leaf extract, 1 part of curcumin, 1 part of sour cherry powder, 1 part of bonito peptide, 1 part of aronia melanocarpa, 1 part of celery seed extract, 1 part of grape seed extract and 1 part of silybum marianum extract.
4. The composition for improving gout efficacy according to any one of claims 1 to 3, wherein: the composition can be added with one or more Chinese medicinal materials for improving or treating concurrent symptoms.
5. The composition for improving gout according to any one of claims 1 to 3, for use in preparing foods, medicines or health products for improving gout.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911332413.9A CN111000973A (en) | 2019-12-22 | 2019-12-22 | Composition with gout improving effect and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911332413.9A CN111000973A (en) | 2019-12-22 | 2019-12-22 | Composition with gout improving effect and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111000973A true CN111000973A (en) | 2020-04-14 |
Family
ID=70117747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911332413.9A Pending CN111000973A (en) | 2019-12-22 | 2019-12-22 | Composition with gout improving effect and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111000973A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112806568A (en) * | 2021-03-29 | 2021-05-18 | 吉林农业大学 | Edible plant composition food with anti-gout function |
| CN116326783A (en) * | 2023-01-10 | 2023-06-27 | 时代生物科技（深圳）有限公司 | Composition with skin moisture improving and antioxidant functions and preparation method thereof |
| CN117695369A (en) * | 2023-11-28 | 2024-03-15 | 广州飞来爱生命科技有限公司 | Uric acid balance endocrine reducing compound preparation and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101475576A (en) * | 2009-02-02 | 2009-07-08 | 温州医学院 | Flavone lignose compound, and preparation and pharmaceutical use thereof |
| CN109452521A (en) * | 2018-12-26 | 2019-03-12 | 广东养慕特殊医用食品有限公司 | A kind of anti-trioxypurine peptide solid beverage, Preparation method and use |
| CN109758571A (en) * | 2019-03-27 | 2019-05-17 | 长春健康未来医药科技有限公司 | A kind of promotion uric acid metabolism improves gout, the composition of Saving cortilage and preparation method thereof |
| CN109805235A (en) * | 2018-12-26 | 2019-05-28 | 广东养慕特殊医用食品有限公司 | A kind of drop four high wheat perfume (or spice) complex polypeptide solid beverages, Preparation method and use |
-
2019
- 2019-12-22 CN CN201911332413.9A patent/CN111000973A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101475576A (en) * | 2009-02-02 | 2009-07-08 | 温州医学院 | Flavone lignose compound, and preparation and pharmaceutical use thereof |
| CN109452521A (en) * | 2018-12-26 | 2019-03-12 | 广东养慕特殊医用食品有限公司 | A kind of anti-trioxypurine peptide solid beverage, Preparation method and use |
| CN109805235A (en) * | 2018-12-26 | 2019-05-28 | 广东养慕特殊医用食品有限公司 | A kind of drop four high wheat perfume (or spice) complex polypeptide solid beverages, Preparation method and use |
| CN109758571A (en) * | 2019-03-27 | 2019-05-17 | 长春健康未来医药科技有限公司 | A kind of promotion uric acid metabolism improves gout, the composition of Saving cortilage and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 王毅兴等: "中医药治疗高尿酸血症的实验研究进展" * |
| 胡伟琼等: "痛风急性和慢性期分子机制研究进展" * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112806568A (en) * | 2021-03-29 | 2021-05-18 | 吉林农业大学 | Edible plant composition food with anti-gout function |
| CN116326783A (en) * | 2023-01-10 | 2023-06-27 | 时代生物科技（深圳）有限公司 | Composition with skin moisture improving and antioxidant functions and preparation method thereof |
| CN117695369A (en) * | 2023-11-28 | 2024-03-15 | 广州飞来爱生命科技有限公司 | Uric acid balance endocrine reducing compound preparation and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109674958B (en) | Traditional Chinese medicine composition with effect of reducing uric acid and preparation method and application thereof | |
| CN111000973A (en) | Composition with gout improving effect and application thereof | |
| KR101735151B1 (en) | Anti-fatigue composition, formulation and use thereof | |
| CA1243605A (en) | Antidiarrheal compositions and use thereof | |
| CN108112997B (en) | A health food composition | |
| CN101209330A (en) | Compound Chinese medicinal granule with heat-clearing and detoxication, worm-expelling and liver-protecting efficacy | |
| CN101209296A (en) | Chinese medicinal granule with worm-expelling liver-caring, hemostasis and dysentery-stopping efficacy | |
| CN101474271B (en) | Medicament for treating uarthritis | |
| CN111150799A (en) | Composition for preventing and treating hyperuricemia and gout as well as preparation method and application thereof | |
| WO2021042275A1 (en) | Traditional chinese medicine composition for treating osteoarthritis | |
| KR102416513B1 (en) | Composition for preventing and improving pet constipation and manufacturing method thereof | |
| CN114848699B (en) | Composition with uric acid reducing effect and preparation method and application thereof | |
| CN113384612A (en) | Anti-gout composition and preparation method and application thereof | |
| Widjanarko et al. | Laxative potential of the konjac flour (Amorphophallus muelleri Blume) in treatment of loperamide induced constipation on Sprague Dawley rats | |
| KR101824016B1 (en) | Pharmaceutical composition for preventing or treating arthritis comprising extract of Taraxacum platycarpum H. Dahlsi, Saururus chinensis Baill, Lonicera japonica Thunb, Commiphora myrrha Engl., Clematis manshurica Rupr, Alisma orientalis (Sam) Juzep, Akebia quinata Decne, Plantago asiatica L, Ulmus pumila L., Phyllostachys nigra var. henonis (Bean.) Stapf, Cassia tora L, Angelica gigas Nakai, Paeonia lactiflora Pallas and Glycyrrhiza uralensis Fisch. as an active ingradient | |
| CN116370574B (en) | Traditional Chinese medicine composition for preventing and treating gosling gout and preparation method thereof | |
| CN110935002A (en) | Composition with blood pressure lowering effect and application thereof | |
| CN110787273A (en) | Traditional Chinese medicine composition for regulating uric acid and application thereof | |
| CN109125631A (en) | Chinese medicine composition and preparation method thereof with liver kidney regulatory function | |
| CN105030954B (en) | A kind of composition, preparation, preparation method and applications for treating grice diarrhoea | |
| CN112438991B (en) | Medical application of heparin, or derivative thereof, or pharmaceutically acceptable salt thereof | |
| CN103933277A (en) | Tibetan drug for treating gout disease | |
| CN108714158A (en) | Pagatpat fruit is preparing the application in preventing chemical damage drug | |
| CN112674327B (en) | Health-care food | |
| CN111671841B (en) | Anti-osteoarthritis pharmaceutical composition and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |